Mayo Clinic Laboratories > Oncology > Pediatrics

Pediatric cancer

Precision diagnostics for pediatric cancers

For families facing a childhood cancer diagnosis, access to personalized, trustworthy guidance on how to best treat their child’s illness is paramount. Mayo Clinic Laboratories’ testing for childhood malignancy is designed by pediatric oncology experts to evaluate targetable mutations for individualized insights that can confirm diagnosis and guide treatment selection.

1 in 8

1 in 8 patients have a germline variant1

50+

50+ hereditary cancer syndromes have been described2

33%

33% of patients identified to have germline variants benefit from tailored cancer treatment3

Hereditary cancers Hereditary cancers
Hereditary cancers

Mayo Clinic Laboratories’ pediatric hereditary cancer test offerings include single gene assays that evaluate specific genes already identified in a parent with a hereditary cancer syndrome.

Neuro-oncology Neuro-oncology
Neuro-oncology

Our pediatric-focused neuro-oncology testing includes both comprehensive MayoComplete next-generation sequencing and chromosomal microarray. Used in combination, these tests provide robust coverage of established and emerging cancer-related gene expression, including mutations, rearrangements, fusions, and copy number variants.

Soft tissue cancer Soft tissue cancer
Soft tissue cancer

Our next-generation sequencing sarcoma fusion panel assesses for fusions described in 39 subtypes of soft tissue, bone, and other mesenchymal tumors. Because fusion events can occur between known or novel gene partners, the panel is designed to provide the most comprehensive analysis by including 124 gene fusion pairs, 274 fusion variants, and novel gene partner detection.

News and updates

The latest

Chromosomal microarray better informs brain tumor diagnosis

Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.

Learn more
Chromosomal microarray better informs brain tumor diagnosis

Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.

New gene panel enhances brain tumor profiles

Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.

Hereditary Oncology Testing [Test in Focus]

Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.

Hereditary oncology: Molecular testing for solid tumors

In this episode of Lab Medicine Rounds, Sounak Gupta, M.B.B.S., Ph.D., assistant professor of Laboratory Medicine and Pathology at Mayo Clinic, discusses hereditary oncology and the importance of performing molecular testing of solid tumors.

References
  1. Lee J, Gillam L, Visvanathan K, Hansford J, McCarthy M. Clinical utility of precision medicine in pediatric oncology: a systemic review. JCO Precision Oncology. 2021:5,1088-1102.
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.